Introduction of Biopharmaceuticals in Europe: A Cross-Sectional Study of Early Diffusion Patterns and Data Availability
Authors:
- Ivar VeszeleiIVIvar Veszelei
- Brian GodmanBGBrian Godman
- Katri AaltonenKAKatri Aaltonen
- Gisbert W. SelkeGSGisbert W. Selke
- Kristina GaruolienėKGKristina Garuolienė
- Agnese CanginiACAgnese Cangini
- Amanj KurdiAmanj Kurdi
- António Teixeira RodriguesARAntónio Teixeira Rodrigues
- Caridad PontesCPCaridad Pontes
- Carla TorreCTCarla Torre
- Carlotta LunghiCarlotta Lunghi
- Edel BurtonEBEdel Burton
Open Access
- 8 August 2025
- journal article
- Published by Springer Nature in BioDrugs
- Vol. 39 (5) , 735-751
Abstract
Biopharmaceuticals add value in the treatment of many diseases but different health systems in Europe face clinical and economic challenges with introducing them. Joint efforts across Europe are therefore essential to ensure their sustainable and equitable use. However, to date few cross-national comparative studies have assessed their introduction. This study aimed to assess the availability of health authority data and variation in the early diffusion of biopharmaceuticals across Europe. A cross-sectional study was undertaken to analyze the diffusion of 17 biopharmaceuticals, approved between 2015 and 2019, among European countries between 2015 and 2022. The study assessed data availability, diffusion rates measured as accumulated defined daily doses per 1000 inhabitants, as well as relative rankings between countries during the first 4 years following market authorization. Twenty countries and two regions out of 31 European countries provided data on biopharmaceutical utilization for out-of-hospital care, 15 provided wholesaler data, and 14 provided hospital data. Certain countries and regions contributed data in multiple categories, while six did not provide any data. Diffusion rates were assessed for 17 countries and two regions, which showed appreciable variation, with secukinumab and erenumab being introduced in most countries and follitropin delta and tildrakizumab in the least number of countries. Germany, Austria, and Norway demonstrated the highest early diffusion rates, while Lithuania, Romania, and Latvia had the lowest. This study revealed a substantial variation between European countries and regions in the early diffusion of biopharmaceuticals and the availability of data to monitor their use. The reasons behind these patterns require further investigation to support European countries in optimizing the use of biopharmaceuticals to reach an equitable and cost-effective use of medicines across Europe.Keywords
Funding Information
- Uppsala University
This publication has 83 references indexed in Scilit:
- Variations in criteria regulating treatment with reimbursed biologic DMARDs across European countries. Are differences related to country's wealth?Annals of the Rheumatic Diseases, 2014
- Inequities in access to biologic and synthetic DMARDs across 46 European countriesAnnals of the Rheumatic Diseases, 2014
- The debate about the funding of Herceptin: A case study of ‘countervailing powers’Social Science & Medicine, 2012
- Patients’ access to biologics in rheumatoid arthritis: a comparison between Portugal and other European countriesThe European Journal of Health Economics, 2012
- Market uptake of orphan drugs - a European analysisJournal of Clinical Pharmacy and Therapeutics, 2012
- Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countriesMedical Science Monitor, 2011
- European network for Health Technology Assessment, EUnetHTA: Planning, development, and implementation of a sustainable European network for Health Technology AssessmentInternational Journal of Technology Assessment in Health Care, 2009
- Enhancing the rational use of new medicines across European health care systemsEuropean Journal of Clinical Pharmacology, 2008
- Factors affecting the uptake of new medicines in secondary care a literature reviewJournal of Clinical Pharmacy and Therapeutics, 2008
- The history of the Drug Utilization Research Group in EuropePharmacoepidemiology and Drug Safety, 2005